STEPHEN MATARESE, DO
Pulmonary Disease Physician in WARWICK, Rhode Island. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
STEPHEN MATARESE, DO filed 3,221 Medicare Part D claims in 2023 as a Pulmonary Disease Physician in WARWICK, Rhode Island, prescribing 50% generic.
- 3K
- Part D claims, 2023
- 50%
- generic prescribing
- $18.81
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
STEPHEN MATARESE, DO's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023 — across all CMS prescribers nationally
3,221 Top 11% higher than 89% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
STEPHEN MATARESE, DO practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about STEPHEN MATARESE, DO?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in Rhode Island
How Pulmonary Disease Physician compares to other specialties among Rhode Island providers
Pulmonary Disease Physician share within Rhode Island
Pulmonary Disease Physician is one of the more visible NUCC categories in Rhode Island
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Pulmonary Disease Physician (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Pulmonary Disease Physician ABMS/AOA estimate
Est. board-certified rate (Pulmonary Disease Physician) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Pulmonary Disease Physician US NPIs
Specialty board-certified rate — Pulmonary Disease Physician estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
STEPHEN MATARESE, DO appears in the CMS NPPES registry as a Pulmonary Disease Physician provider holding DO credentials at 215 TOLL GATE RD, WARWICK, RI, 02886, with a listed phone of (401) 732-1508. NPI 1225016355 was issued on 01/09/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what MATARESE most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 3,221 prescription claims written by this provider, covering 368 Medicare beneficiaries and totaling roughly $1.5 million in drug spend, split 50% brand-name and 50% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Pulmonary Disease Physician is a mid-sized specialty nationwide, with 9,271 enrolled providers across 53 states and an average of 1,457 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1225016355 |
|---|---|
| Specialty | Pulmonary Disease Physician |
| Credentials | DO |
| Gender | Male |
| NPI Issued | 01/09/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm STEPHEN MATARESE, DO's current license status, disciplinary history, and board certifications with the Rhode Island Board of Medical Licensure and Discipline in Rhode Island before relying on this page for a clinical or care decision.
How we sourced this profile
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for STEPHEN MATARESE, DO. Source: openpaymentsdata.cms.gov.
Total received
$19
Largest payer
GlaxoSmithKline, LLC.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Brand-heavy
50% brand-name claims vs 50% generic, on 3,221 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 4,837
- Total Day Supply
- 138,970
- Brand vs Generic
- 50% brand / 50% generic
- Brand Drug Cost
- $1.5M
- Antibiotic Claims
- 109
Patient Demographics
- Average Patient Age
- 74.7 years
- Avg HCC Risk Score
- 1.46
- Gender Split
- 53% female / 47% male
- Age Distribution
- <65: 30, 65-74: 152, 75-84: 145, 85+: 41
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What STEPHEN MATARESE, DO prescribes most
Top Medicare Part D drugs by claim count, 2023
- Albuterol Sulfate …
Albuterol Sulfate Hfa
294 claims
- Trelegy Ellipta
Trelegy Ellipta
282 claims
- Montelukast Sodium
Montelukast Sodium
245 claims
- Pramipexole Dihydr…
Pramipexole Dihydrochloride
142 claims
- Breo Ellipta
Breo Ellipta
138 claims
- Symbicort
Symbicort
127 claims
- Anoro Ellipta
Anoro Ellipta
125 claims
- Zolpidem Tartrate 103
Zolpidem Tartrate
103 claims
| Drug | Claims |
|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 294 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 282 |
| Montelukast Sodium | 245 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 142 |
| Breo Ellipta Fluticasone/Vilanterol | 138 |
| Symbicort Budesonide/Formoterol Fumarate | 127 |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 125 |
| Zolpidem Tartrate | 103 |
| Ventolin Hfa Albuterol Sulfate | 99 |
| Prednisone | 91 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Pulmonary Disease Physician Overview
How STEPHEN MATARESE, DO fits within the Pulmonary Disease Physician landscape nationally.
STEPHEN MATARESE, DO's 3,221 claims are above the specialty average of 1,457.
Nearby Pulmonary Disease Physician Providers in Rhode Island
Other clinicians with the same primary specialty enrolled in Rhode Island, drawn from the same CMS NPPES roster as MATARESE.
Compare Pulmonary Disease Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Rhode Island
Frequently Asked Questions
What is STEPHEN MATARESE, DO's specialty? ▼
How much does STEPHEN MATARESE, DO prescribe under Medicare Part D? ▼
Where is STEPHEN MATARESE, DO located? ▼
What is STEPHEN MATARESE, DO's NPI number? ▼
Does STEPHEN MATARESE, DO prescribe more brand-name or generic drugs? ▼
How many Pulmonary Disease Physician providers are there in the US? ▼
What drugs does STEPHEN MATARESE, DO prescribe most often? ▼
Does STEPHEN MATARESE, DO accept Medicare? ▼
How can I verify STEPHEN MATARESE, DO's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology